Back to Search Start Over

P105 Deglycosylated bleomycin has the antitumor activity of bleomycin without pulmonary toxicity

Authors :
Burgy , Olivier
Wettstein , Guillaume
Bellaye , Pierre-Simon
Decologne , Nathalie
Racoeur , Cindy
Goirand , Françoise
Beltramo , Guillaume
Hernandez , Jean-Francois
Kenani , Abderraouf
Camus , Philippe
Bettaieb , Ali
Garrido , Carmen
Bonniaud , Philippe
Lipides - Nutrition - Cancer (U866) ( LNC )
Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA )
Laboratoire d'Immunologie et Immunothérapie des Cancers ( LIIC )
École pratique des hautes études ( EPHE ) -Université de Bourgogne ( UB )
Université de Montpellier ( UM )
Faculté de Médecine de Monastir [Tunisie]
Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon )
Service de Pneumologie Soins Intensifs, Appareillage Respiratoire [CHU de Dijon]
Lipides - Nutrition - Cancer (U866) (LNC)
Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)
Laboratoire d'Immunologie et Immunothérapie des Cancers (LIIC)
École pratique des hautes études (EPHE)
Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université de Bourgogne (UB)
Université de Montpellier (UM)
Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)
Source :
QJM: An International Journal of Medicine, QJM: An International Journal of Medicine, Oxford University Press (OUP), 2016, 109 (suppl_1), pp.S58. 〈https://academic.oup.com/qjmed/article-abstract/109/suppl_1/S58/2565712/P105-Deglycosylated-bleomycin-has-the-antitumor?redirectedFrom=fulltext〉. 〈10.1093/qjmed/hcw120.006〉, QJM: An International Journal of Medicine, Oxford University Press (OUP), 2016, 109 (suppl_1), pp.S58. ⟨10.1093/qjmed/hcw120.006⟩
Publication Year :
2016
Publisher :
HAL CCSD, 2016.

Abstract

IF 2.824; International audience; Bleomycin is an anti-cancer drug used to treat different malignancies, mainly lymphomas, germ cell tumors. Unfortunately, bleomycin has major, pulmonary toxicity that affects 20% of treated individuals with pulmonary fibrosis being the most devastating form. Deglyco-bleomycin is a molecule derived from bleomycin in which the sugar residue D-mannosyl-L-glucose disaccharide has been deleted. The objective of this study is to assess the anti-cancerous activity and the lung toxicity of deglyco-bleomycin.We compared in vivo the antitumor activity in three rodent models after intraperitoneal administrated deglyco-bleomycin and bleomycin. Pulmonary toxicity was in depth examined after intratracheal administration of both chemotherapeutic agents.We demonstrate in vivo in rodent cancer models, including a human Hodgkin lymphoma xenograft and a syngeneic melanoma model, that intra-peritoneal deglyco-bleomycin is as effective as bleomycin...

Details

Language :
English
ISSN :
14602725 and 14602393
Database :
OpenAIRE
Journal :
QJM: An International Journal of Medicine, QJM: An International Journal of Medicine, Oxford University Press (OUP), 2016, 109 (suppl_1), pp.S58. 〈https://academic.oup.com/qjmed/article-abstract/109/suppl_1/S58/2565712/P105-Deglycosylated-bleomycin-has-the-antitumor?redirectedFrom=fulltext〉. 〈10.1093/qjmed/hcw120.006〉, QJM: An International Journal of Medicine, Oxford University Press (OUP), 2016, 109 (suppl_1), pp.S58. ⟨10.1093/qjmed/hcw120.006⟩
Accession number :
edsair.dedup.wf.001..44e1c41a440d75415ab85e6977279554